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Introduction
The most common early lethal complication is an early 
ventricular fibrillation (EVF) following acute coronary 
syndrome (ACS) or acute myocardial infarction (AMI) 
(1,2). Ventricular arrhythmias occur in 80–85% within 
48 hours after the event. Early or primary ventricular 
fibrillation (PVF) develops in 48–72 hours after the start 
of the myocardial infarction (MI) symptoms and has no 
relationship to any recurrent ischaemia or heart failure.
The rate of death, including sudden cardiac death (SCD) is 
the highest in the early phase after a MI. There is no special 
guidance, how to treat MI patients suffering EVF, no protocol 
about their secondary prevention, among others early 
implantable cardioverter defibrillator (ICD) implantation. 
Current guidelines do not suggest prevention of SCD within 
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40 days (3). According to the guidelines, ICD therapy is 
recommended to prevent SCD for patients with symptomatic 
heart failure (NYHA Class II–III) and left ventricular 
ejection fraction (LVEF) ≤35% despite optimal medical 
therapy but just 6 weeks past the event. Earlier (<40 days) 
ICD implantation or the use of wearable cardioverter 
defibrillator may be considered in a selected patient group—
incomplete revascularization, pre-existing LVEF dysfunction 
or occurrence of malignant arrhythmias 48 hours after ST-
segment elevation MI (STEMI) (1,4). However, there are 
conflicting results regarding the prognosis of EVF survivors 
(2,5). EVF has a significant effect on in-hospital mortality (6). 
Even in the percutaneous coronary intervention (PCI), PCI-
era, acute phase of ventricular tachyarrhythmia (VT) or 
ventricular fibrillation (VF) was associated with higher in-
hospital mortality in case of STEMI (7). Solomon et al. found 
that the risk of SCD is the highest within 30 days after the 
MI in patients with reduced EF or heart failure. The rate of 
SCD is 1.4% in the first month, and 0.14% in 2 years (8). On 
the other hand there are results suggesting that prophylactic 
ICD therapy does not reduce overall mortality (3), not even 
in high-risk patients but was associated with reduction of 
death due to arrhythmia (9). 
In a high-volume, modern PCI-centrum, in order to be able 
to manage the great number of patients, after couple of days 
they are either discharged home, to a rehabilitation facility or 
transferred to another hospital for further evaluation.
The present study was designed to assess the survival of 
MI patients with EVF after the guideline recommended 
6-week time period. It is evident that the patients’ general 
condition has an effect on the prognosis. But there is no 
data whether it is safe to wait 6 weeks with the decision. 
There may be a high-risk patient group that would benefit 
from an early judgment and more specialised treatment at a 
cardiac centrum. In order to find the clinical characteristics 
of the high-risk patients, we aimed to examine whether 
the general condition of the patients at discharge has any 
relation to the prognosis. 
Methods 
Patient population, data collection
A total of 11,582 patients with ACS have been revascularised 
between 2005 and 2013 at our Institution. These 
consecutive patients were enrolled to a registry, named 
Városmajor Myocardial Infarction Registry (VMAJOR-MI 
Registry), in which all the available demographic (gender, 
date of birth, date of admission, date of death) and clinical 
patient data—laboratory findings [troponin T, creatine 
kinase-MB (CK-MB), creatinine, glucose, cholesterol, low-
density lipoprotein (LDL)-cholesterol], type of infarction 
[STEMI,  non-STEMI (NSTEMI)]—results  from 
echocardiography (LVEF), coronary angiography—have 
been summarised. The acute event has been characterised 
by its severity—complicated by EVF, cardiogenic shock, on 
site resuscitation—and by its complications—heart failure, 
invasive respiratory treatment. EVF-positive patients’ data 
has been supplemented by the following factors: laboratory 
parameters [potassium, white blood cell (WBC) count, 
C-reactive protein (CRP)], detailed coronary-status (number 
of vessels affected, number of vessels treated by PCI).
Two groups were created based on the fact that AMI was 
complicated by EVF or not. VF requiring defibrillation in 
the first 48 hours of the peri-hospital period was used as a 
definition of EVF. Other types of ventricular arrhythmias, 
such as ventricular tachycardia was not examined. Patient 
group with EVF was further divided regarding their general 
condition (good vs. poor). We evaluated the patients’ clinical 
characteristics at discharge. Patients who were released home 
or to a cardiac rehabilitation facility and did not require further 
in-patient cardiac care (no heart failure, no recurrent malignant 
arrhythmia) created the good general condition patient group. 
To the poor general condition group, we enrolled patients 
who died at our institution or were transferred to another 
department on invasive respiratory treatment or needed further 
in-patient cardiac care because of heart failure, arrhythmias or 
any other even non-cardiac reasons. 
Only patients with primary revascularization were 
included into the study which was defined as PCI in the 
first 12 h of symptom onset (10). Patients undergoing 
coronary artery bypass grafting surgery were not eligible for 
the study, as well as we excluded those who were managed 
conservatively. Coronary stenosis was evaluated from 
multiplane projections and a luminal diameter reduction of 
>50% was considered significant. 
The study protocol conformed to the ethical guidelines of 
the 1975 Declaration of Helsinki and was approved in advance 
by the locally appointed ethics committee (30088-2/2014/
EKU). The primary outcome of the study was all-cause 
mortality. The National Health Care Institute provided the 
accurate details on the above endpoint with occurrence dates.
Statistical methods
The analysis was performed using Statistica 13.2 statistical 
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software. Continuous variables were expressed as mean 
and standard deviation (mean ± SD), categorical variables 
were summarized as sample size (n) and frequencies. For 
assessment of normality of distribution, Shapiro-Wilks test 
was used. Levene’s test was used to evaluate homogeneity 
of variances. Student’s t-test was used for comparison of 
normally distributed data and Mann-Whitney U test for 
not normally distributed data. Categorical variables were 
compared using Chi-square test. For offline data analysis 
and graph creation a commercial software package was used 
(Microsoft Excel 2016).
Results
The clinical characteristics of the potentially high-risk 
patients in poor general condition has been compared to 
the assumed low-risk good general condition patient group. 
Detailed results are presented in Table 1. Those in poor 
Table 1 Differences in clinical parameters according to the general condition of patients with early ventricular fibrillation
Variables Poor general condition* Good general condition** P value
Mean age (years) 67.00±11.99 63.00±13.12 0.0004
Male gender (%) 69.66% (124/178) 66.22% (245/370) 0.2528
Mean body mass index (kg/m2) 27.50±4.92 28.10±5.20 0.1336
Mean peak troponin (ng/L) 4,299.00±5,040.43 3,290.00±4,830.04 0.0465
Mean CK (UI/L) 4,070.00±7,191.80 1,879.00±2,142.77 <0.0001
Mean lactate dehydrogenase (U/L) 2,665.00±3,533.94 1,264.00±1,061.65 <0.0001
Mean creatinine (μmol/L) 134.00±82.37 89.00±32.60 <0.0001
Mean cholesterol (mmol/L) 4.00±1.45 4.60±1.39 <0.0001
Mean LDL (mmol/L) 2.47±1.26 2.90±1.43 0.0018
Mean potassium (mmol/L) 4.20±0.74 4.0±0.60 0.0006
Mean white blood cell (mmol/L) 16.60±6.57 13.30±5.16 <0.0001
Mean C-reactive protein (mg/L) 40.20±59.10 21.30±41.31 <0.0001
Mean LVEF 37.000±11.850 46.000±10.997 <0.0001
LVEF <40% 52.11% (74/142) 23.26% (77/331) <0.0001
Diabetes mellitus 69.28% (115/166) 51.97% (185/356) 0.0015
ST-elevation myocardial infarction 64.02% (105/164) 73.80% (262/355) 0.0308
Heart failure 39.33% (70/178) 22.16% (82/370) 0.0106
Cardiogenic shock 40.45% (72/178) 7.30% (27/370) 0.0008
Cardiopulmonary resuscitation 56.18% (100/178) 26.76% (99/370) <0.0001
Invasive respiratory treatment 82.58% (147/178) 31.08% (115/370) <0.0001
VF before revascularization 85.39% (152/178) 71.62% (265/370) 0.0007
VF during revascularization 3.37% (6/178) 20.81% (77/370) 0.1502
VF after revascularization <48 h 11.24% (20/178) 7.57% (28/370) <0.0001
Mean survival time (days) 260.00±728.86 2146.40±1310.50 <0.0001
30-day mortality 74.72% (133/178) 5.68% (21/370) <0.0001
1-year mortality 86.52% (154/178) 14.32% (53/370) <0.0001
*, patients who died at our institution or were transferred to another department on invasive respiratory treatment or needed further in-
patient cardiac care; **, patients who were released home or to a cardiac rehabilitation facility and did not require further in-patient cardiac 
care. CK, creatine kinase; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; VF, ventricular fibrillation.
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condition were older (67 vs. 63 years, P=0.0004), more 
likely to have diabetes (69.28% vs. 51.97%, P=0.0015), 
reduced left ventricle and kidney function. They had higher 
cardiac biomarker, peak troponin T levels (4,299 vs. 
3,290 ng/L, P=0.0465), higher lactate dehydrogenase 
(LDH) levels (2,665 vs. 1,264 U/L) meaning more necrosis, 
larger infarct size. Inflammatory parameters were elevated 
as well, CRP (40.20 vs. 21.30 mg/L, P<0.0001), WBC count 
(16.60 vs. 13.30 mmol/L, P<0.0001). The acute event was 
more severe: heart failure (39.33% vs. 22.16%, P=0.0106), 
cardiogenic shock (40.45% vs. 7.30%, P=0.0008). 
The impact of the extent of the disease and its invasive 
treatment on 6-week mortality based on the general 
condition of the patients is presented in Table 2. Three-
vessel disease complicated with poor condition was 
associated with higher 6-week mortality (93.02%, 40/43; 
P=0.0043). The extent of the coronary artery disease (CAD) 
had no impact on mortality in patients with good condition. 
There were 25 patients discharged in good condition 
who died within 6 weeks. Comparing their clinical data to 
those who survived, the following factors were found to be 
significant: mean age (74 vs. 62 years, P=0.0119), diabetes 
(83.33% vs. 49.70%, P=0.0022), mean troponin T (5,764 vs. 
3,137 ng/L, P=0.0161), LVEF <40% (59.09% vs. 21.71%, 
P=0.0023), more severe acute event—heart failure (52.00% 
vs. 20.00%, P=0.0073), invasive respiratory treatment 
(72.00% vs. 28.12%, P=0.0002). Full analysis is presented in 
Table 3. Differences between EVF-negative patients dying 
within 6 weeks vs. EVF-positive patients in good general 
condition dying within 6 weeks is shown in Table 4. Besides 
diabetes, there was no significant difference between the 
two groups. 
Our results are based on a registry in which the data 
of the index ACS has been collected between 2005 and 
2013. We use this database as background for long-term 
follow-up. This timeframe does not affect the results, 
since the guidelines and the policy of our institute about 
revascularisation have not change.
Discussion
Following AMI there is an increased risk of SCD, especially 
showing reduced LVEF (<40%) or frequent ventricular 
premature beats (VPBs). In high-risk post-MI patients, the 
risk of arrhythmic death (AD) is higher for up to 2 years. 
However, risk stratification for ICD would be optimal 
in the first 6 months, noticing that the chance for both 
arrhythmic and non-AD is the highest within 6 months (11). 
Theoretically, ICD implantation following AMI and 
revascularization would save lives due to presence of higher 
SCD incidence (12). Although ICD implantation for 
both secondary and primary prevention has been shown 
reducing all-cause mortality, DINAMIT and IRIS trials 
demonstrated that early ICD implantation within 40 days 
does not reduce mortality in high-risk post-MI patients. 
Table 2 The impact of the extent of disease and its invasive 
treatment on 6-week mortality based on the general condition of 
patients with early ventricular fibrillation
Coronary angiography 
results
Total Dead % P value
Poor general condition*
CA
1-vessel disease 69 49 71.01 –
2-vessel disease 45 35 77.78 0.2432
3-vessel disease 43 40 93.02 0.0043
LM included 20 15 75.00 0.3817
PCI
On 1 vessel 111 83 74.77 –
On 2 vessels 35 30 85.71 0.1087
On 3 vessels 8 7 87.50 0.2252
Not performed 24 20 83.33 0.2091
Good general condition**
CA
1-vessel disease 193 8 4.15 –
2-vessel disease 105 6 5.71 0.4464
3-vessel disease 55 9 16.36 0.2073
LM included 15 2 13.33 0.3122
PCI
On 1 vessel 302 15 4.97 –
On 2 vessels 34 5 14.71 0.2357
On 3 vessels 6 0 0 –
Not performed 27 5 18.52 0.1715
*, patients who died at our institution or were transferred to 
another department on invasive respiratory treatment or needed 
further in-patient cardiac care; **, patients who were released 
home or to a cardiac rehabilitation facility and did not require 
further in-patient cardiac care. CA, coronary angiography; 
LM, left main coronary artery; PCI, percutaneous coronary 
intervention.
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Table 3 Differences in clinical parameters of patients leaving institution in good general shape but dying within six weeks vs. survivors
Variables
Patients in good general condition*
Dying within 6 weeks Surviving after 6 weeks P value
Mean age (years) 74.00±9.86 62.00±12.94 0.0119
Male gender 68.00% (17/25) 66.09% (228/345) 0.4333
Mean body mass index (kg/m2) 26.46±3.30 28.20±5.31 0.0752
Diabetes mellitus 83.33% (20/24) 49.70% (165/332) 0.0022
Mean peak troponin (ng/L) 5,764.55±9,246.67 3,137.00±4,418.00 0.0161
Mean creatinine (μg/L) 108.13±34.90 88.00±32.06 0.0017
Mean glucose (mmol/L) 11.02±4.00 8.99±4.56 0.0173
Mean cholesterol (mmol/L) 3.60±1.14 4.67±1.38 0.0004
Mean LDL (mmol/L) 2.06±1.18 3.00±1.43 0.0030
Mean potassium (mmol/L) 4.03±0.88 4.00±0.58 0.4072
Mean white blood cell (mmol/L) 13.90±4.62 13.30±5.20 0.2915
Mean C-reactive protein (mg/L) 50.60±66.80 19.07±37.95 0.0003
LVEF <40% (%) 59.09% (13/22) 20.71% (64/309) 0.0023
STEMI 56.52% (13/23) 75.00% (249/332) 0.0689
Heart failure 52.00% (13/25) 20.00% (69/345) 0.0073
Cardiogenic shock 20.00% (5/25) 6.38% (22/345) 0.1672
On-site CPR 40.00% (10/25) 25.80% (89/345) 0.1694
Respiratory treatment 72.00% (18/25) 28.12% (97/345) 0.0002
VF before revascularisation 76.00% (19/25) 71.30% (246/345) 0.3307
VF during revascularisation 12.00% (3/25) 21.45% (74/345) 0.3470
VF after revascularisation, <48 h 12.00% (3/25) 7.25% (25/345) 0.3857
Mean survival (days) 18.70±11.83 2,300.00±1220.42 <0.0001
*, patients who were released home or to a cardiac rehabilitation facility and did not require further in-patient cardiac care. CPR, 
cardiopulmonary resuscitation; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; STEMI, ST-elevation myocardial 
infarction; VF, ventricular fibrillation.
Table 4 Clinical characteristics of patients dying within 6 weeks. Comparison of patients’ data having early ventricular fibrillation and leaving the 
hospital in good general condition and patients not having early ventricular fibrillation
Characteristics
Patients dying within 6 weeks
P value
Good general condition and VF+ VF−
All cases 6.76% (25/370) 7.88% (902/11,440) 0.4143
Mean age (years) 74.77±9.80 74.62±10.38 0.3430
Male gender 68.00% (17/25) 53.88% (486/902) 0.1253
NSTEMI 43.48% (10/23) 54.53% (469/860) 0.2438
LVEF <40% 59.09% (13/22) 50.54% (372/736) 0.2722
DM 83.33% (20/24) 63.84% (535/838) 0.0368
Creatinine <100 (μmol/L) 50.00% (12/24) 60.00% (513/855) 0.2425
Cardiogenic shock 20.00% (5/25) 29.82% (269/902) 0.3169
On site CPR 40.00% (10/25) 5.99% (54/902) 0.0009
Heart failure 52.00% (13/25) 47.78% (431/902) 0.3821
CPR, cardiopulmonary resuscitation; DM, diabetes mellitus; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-elevation myocardial 
infarction; VF, ventricular fibrillation.
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These findings could be explained by the increase in 
death due to non-arrhythmic causes (e.g., heart failure, 
free wall rupture etc.) (3,9). Based on these results ICD 
implantation for primary prevention in post-MI patients 
is recommended later than 40 days (1,13). In AMI, the 
incidence of ventricular arrhythmias including EVF is about 
2–8% (1,2). However, results according to its significance 
on prognosis is controversial. Masuda et al. stated that acute 
phase VT/VF associated with in hospital mortality even 
in the PCI era, moreover with increased 5-year mortality 
in high-risk patients (GRACE Risk Score >115) (7). In the 
era of routine primary PCI era in STEMI although overall 
STEMI mortality declined, PVF remained as predictor for 
30-day and 1-year mortality (14). Results from the database 
of APEX-AMI trial showed increased 90-day mortality in 
patients with VT/VF presenting for primary PCI (15). On 
the other hand the prospective GISSI-2 trial revealed that 
both early (<4 h) and late (4–48 h) PVF was an independent 
risk factor for in hospital death but post-discharge to 
6 months prognosis was unaffected (16). Other studies 
found similar results, EVF had significant effect only on 
in-hospital mortality (6,17). High short-term survival was 
detected by STEMI patients undergoing PCI and receiving 
drug eluting stents (18). 
Seeing these conflicting results about the post-discharge 
prognosis of EVF patients, comparing patients based on 
their general condition at discharge had the following result. 
Higher age, larger infarct size—meaning higher biomarker 
levels (troponin T, CK), higher LDH, inflammation (WBC 
count, CRP levels), more comorbidities (diabetes, poor renal 
function), more severe acute event resulting in cardiogenic 
shock, heart failure correlates with poor general condition. 
These patients had significantly lower mean survival time, 
high 75% short-term, 30-day and high 86.5% long-term, 
1-year mortality. Being sad that they remain a high-risk 
patient group who would benefit at least from a closer 
follow-up in the 6-week time-period recommended by the 
guidelines. Gheeraert et al. found that out of hospital VF 
in patients with AMI has angiographic determinants (19). 
Considering that the amount of myocardium at risk may 
have an effect on prognosis, we found that the extent of 
the CAD resulted in higher 6-week mortality only in high-
risk patients, in the poor general condition patient group. 
Mortality and the extent of the disease in patients with good 
general condition were not related. The technological impact 
of advances on PCI revascularization has not affected our 
results, being sad that our institute’s invasive approach has 
always been high. PCI rates in NSTEMI patients with EVF 
(81%, 122/151) exceeded percentage seen in literature (20).
We could select those patients in good general condition 
who have low mortality risk in the critical 6-week period—
before they are assessed whether to get an ICD or not. 
However, age, diabetes, reduced LVEF, larger infarct size 
(higher troponin level), NSTEMI, reduced kidney function 
count as risk factors for dying within 6 weeks in spite of 
the good general condition. Overall comparing 6-week 
mortality characteristics of EVF− patients to EVF+ cases in 
good condition, there is no significant difference between 
the two groups. 
The general condition of the patients at discharge 
influence the prognosis. Patients with poor general 
condition and those in good general condition but having 
NSTEMI, reduced LVEF may benefit from a closer follow 
up at a high volume invasive cardiac centrum employing 
telemedicine devices. In assorted cases earlier ICD 
implantation would be beneficial. In conclusion, it is safe to 
say that there is a low risk of dying within the 6-week time 
period offering by the guidelines.
Limitation section 
The most important limitation is that the present study 
was a retrospective observational study with its special 
limitations. Factors affecting the prognosis such as 
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